Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease

Publisher： Karger

E-ISSN： 1421-9670|45|3|257-266

ISSN： 0250-8095

Source： American Journal of Nephrology, Vol.45, Iss.3, 2017-02, pp. : 257-266

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Autosomal Dominant Polycystic Kidney Disease – Clinical and Genetic Aspects

By  

Kidney and Blood Pressure Research, Vol. 25, Iss. 5, 2002-11 ,pp. : 265-283

Karger

Access to resources Recommend Favorite

Autosomal Dominant Polycystic Kidney Disease: New Treatment Options and How to Test Their Efficacy

By  

Kidney and Blood Pressure Research, Vol. 32, Iss. 5, 2009-11 ,pp. : 380-387

Karger

Access to resources Recommend Favorite

Dimensions of Arteriovenous Fistulas in Patients with Autosomal Dominant Polycystic Kidney Disease

By  

Nephron, Vol. 85, Iss. 1, 2000-04 ,pp. : 50-53

Karger

Access to resources Recommend Favorite

Blood Pressure and Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease

By  

Kidney and Blood Pressure Research, Vol. 39, Iss. 6, 2014-12 ,pp. : 630-635

Karger

Access to resources Recommend Favorite

Metabolic Syndrome Components in Patients with Autosomal-Dominant Polycystic Kidney Disease

By  

Kidney and Blood Pressure Research, Vol. 32, Iss. 6, 2009-11 ,pp. : 405-410

Karger

Access to resources Recommend Favorite